Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate baricitinib across diverse therapeutic indications, including rheumatoid arthritis, juvenile idiopathic arthritis, atopic dermatitis, inflammatory myopathies, axial spondyloarthritis, SARS-CoV-2 infection, and chronic kidney disease. Sponsored by industry partners like Eli Lilly and Company alongside academic institutions such as the University of Manchester and Duke University, these studies encompass recruiting, active, completed, and marketing-approved statuses. Notably, several completed Phase 2 and Phase 3 trials have evaluated baricitinib in adult inflammatory myopathies, pediatric juvenile idiopathic arthritis, atopic dermatitis, and SARS-CoV-2 treatment.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07222137 RECRUITING
Diabetes Mellitus, Type 1
Eli Lilly and Company
 2026-01-12 PHASE3
NCT03773965 RECRUITING
Juvenile Idiopathic Arthritis
Eli Lilly and Company
 2019-04-05 PHASE3
NCT06923072 RECRUITING
Kohlmeier-Degos Disease; Malignant Atrophic Papulosis; Degos Disease; Papulosis, Malignant Atrophic
National Heart, Lung, and Blood Institute (NHLBI)
 2026-02-18 PHASE2
NCT07543458 NOT_YET_RECRUITING
Dengue; Severe Dengue; Mosquito-Borne Diseases; Vector Borne Diseases; Arbovirus Infections; Flavivirus Infections; RNA Virus Infections; Hemorrhagic Fever
Oxford University Clinical Research Unit, Vietnam
 2026-10-01 PHASE3
NCT07262983 RECRUITING
Hyper IgE Syndrome From STAT3 Mutation; Job s Syndrome; HIES; Lupus; Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
 2026-09-09 PHASE1
NCT07003997 RECRUITING
Major Depressive Disorder
Emory University
 2025-09-03 PHASE2
NCT05651880 NOT_YET_RECRUITING
Active Non-anterior Non-infectious Uveitis
University Hospital, Rouen
 2026-07 PHASE3
NCT07268534 NOT_YET_RECRUITING
Folliculitis Decalvans (FD)
Assistance Publique - Hôpitaux de Paris
 2026-04-01 PHASE2
NCT07779642 NOT_YET_RECRUITING
ARDS (Acute Respiratory Distress Syndrome); Acute Hypoxic Respiratory Failure
University of Colorado, Denver
 2026-09 PHASE2
NCT07081763 NOT_YET_RECRUITING
HIV-1-infection
ANRS, Emerging Infectious Diseases
 2026-05 PHASE2
NCT06687551 RECRUITING
Rheumatoid Arthritis (RA
University Hospital, Toulouse
 2025-06-06 PHASE4
NCT07279688 RECRUITING
Polymyalgia Rheumatica (PMR)
University Hospital, Brest
 2025-12-18 PHASE3
NCT04381936 RECRUITING
Pneumonia
University of Oxford
 2020-03-19 PHASE3
NCT06490757 RECRUITING
Inflammatory Hepatocellular Adenoma
Assistance Publique - Hôpitaux de Paris
 2024-10-02 PHASE2
NCT06381661 RECRUITING
Sepsis
Assistance Publique - Hôpitaux de Paris
 2026-07-09 PHASE2
NCT06868381 NOT_YET_RECRUITING
Cardiac Sarcoidosis
Stanford University
 2026-04-01 PHASE2
NCT07222332 RECRUITING
Diabetes Mellitus, Type 1
Eli Lilly and Company
 2026-02-05 PHASE3
NCT03414502 RECRUITING
Rheumatoid Arthritis
University of Nebraska
 2007-12-10 PHASE3
NCT05723198 RECRUITING
Areata Alopecia; Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Pathological Conditions, Anatomical
Eli Lilly and Company
 2023-02-27 PHASE3
NCT04972760 RECRUITING
Dermatomyositis
Assistance Publique - Hôpitaux de Paris
 2022-08-31 PHASE3
NCT07209267 NOT_YET_RECRUITING
HIV Infection; HIV
Emory University
 2026-10 PHASE2
NCT05452564 RECRUITING
Human Immunodeficiency Virus
William Tyor
 2023-05-18 PHASE2
NCT05858515 WITHDRAWN
Post-Acute COVID-19 Syndrome
Vanderbilt University Medical Center
 2024-10-21 PHASE3
NCT07669675 NOT_YET_RECRUITING
ITP - Immune Thrombocytopenia
Peking University People's Hospital
 2026-07-01 PHASE2
NCT07535645 NOT_YET_RECRUITING
Persistent Thrombocytopenia; Allogeneic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital
 2026-04-15 PHASE1; PHASE2
NCT07554222 RECRUITING
Healthy; Active Non-segmental Vitiligo; Severe Alopecia Areata
Innovent Biologics (Suzhou) Co. Ltd.
 2026-04-18 PHASE1
NCT05849038 RECRUITING
HIV; Depression; Anhedonia
Emory University
 2023-12-11 PHASE2
NCT07608796 NOT_YET_RECRUITING
Depressive Symptoms; Cognitive Symptom
Emory University
 2026-09 PHASE2
NCT07449910 NOT_YET_RECRUITING
Acute Ichemic Stroke; Anterior Cerebral Artery Stroke; Baricitinib
The First Affiliated Hospital of University of Science and Technology of China
 2026-03-17 PHASE2; PHASE3
NCT05003310 RECRUITING
Rheumatoid Arthritis
Galvani Bioelectronics
 2021-10-19
NCT06849908 RECRUITING
Behcet Syndrome, Intestinal Type
Peking Union Medical College Hospital
 2024-11-08 PHASE2
NCT05792462 ACTIVE_NOT_RECRUITING
NMO Spectrum Disorder
Tianjin Medical University General Hospital
 2023-04-15 PHASE1
NCT04870203 ACTIVE_NOT_RECRUITING
Rheumatoid Arthritis
University Hospital, Bordeaux
 2021-07-15 PHASE3
NCT06439615 NOT_YET_RECRUITING
Spontaneous Subarachnoid Hemorrhage
Tang-Du Hospital
 2024-08-01 PHASE2
NCT06631287 RECRUITING
Long COVID; Sars-CoV-2 Infection; Coronavirus Infections; COVID-19
Wes Ely
 2024-10-21 PHASE3
NCT06240351 ACTIVE_NOT_RECRUITING
Frontal Fibrosing Alopecia
University of Alabama at Birmingham
 2024-04-22 PHASE4
NCT04088396 ACTIVE_NOT_RECRUITING
Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company
 2020-02-12 PHASE3
NCT06158113 ACTIVE_NOT_RECRUITING
Lichen Planus, Oral; Lichen Planus, Mucosal; Oral Lichen Planus
University of North Carolina, Chapel Hill
 2024-03-13 PHASE2
NCT05300932 ACTIVE_NOT_RECRUITING
Systemic Sclerosis
Tongji Hospital
 2022-03-08 PHASE4
NCT06065046 RECRUITING
Traumatic Brain Injury
Tang-Du Hospital
 2023-11-24 PHASE2
NCT06548802 UNKNOWN
Pulmonary Injury After Intracerebral Hemorrhage
Tianjin Medical University General Hospital
 2024-02-29 PHASE1; PHASE2
NCT06768294 NOT_YET_RECRUITING
Calcium Pyrophosphate Deposition Disease; Chondrocalcinosis
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
 2025-01 PHASE2
NCT07028385 COMPLETED
HIV
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
 2025-09-22 PHASE2
NCT05237388 COMPLETED
Chronic Kidney Diseases
Duke University
 2023-04-20 PHASE2
NCT07357649 NOT_YET_RECRUITING
Rheumatoid Arthritis
Tanta University
 2026-01 PHASE4
NCT02735707 RECRUITING
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht
 2016-04-11 PHASE3
NCT05955066 RECRUITING
Rheumatoid Arthritis
Chinese University of Hong Kong
 2023-12-01 PHASE4
NCT06797310 NOT_YET_RECRUITING
Alopecia Areata
National Taiwan University Hospital
 2025-01-23 PHASE2
NCT06977035 RECRUITING
Rheumatoid Arthritis
Sohag University
 2025-05-05
NCT05914584 UNKNOWN
Hospital-acquired Pneumonia
Nantes University Hospital
 2023-07-01 PHASE2; PHASE3
NCT06737705 COMPLETED
Intracerebral Hemorrhage
De-zhi Kang
 2025-01-01 PHASE2
NCT06768840 RECRUITING
Vitiligo, Generalized
South Valley University
 2024-10-02 PHASE2; PHASE3
NCT03915964 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2019-04-25 PHASE4
NCT04086745 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2020-02-14 PHASE4
NCT05524311 COMPLETED
Juvenile Dermatomyositis
Assistance Publique - Hôpitaux de Paris
 2022-11-10 PHASE2
NCT06936215 RECRUITING
Diffuse Cutaneous Systemic Sclerosis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
 2024-01-01 PHASE3
NCT05852171 UNKNOWN
Mastitis Chronic; Idiopathic Granulomatous Mastitis
First Affiliated Hospital of Zhejiang University
 2023-05-04 PHASE2
NCT05969730 COMPLETED
Atopic Dermatitis
Mazandaran University of Medical Sciences
 2023-08-15
NCT05189106 COMPLETED
Amyotrophic Lateral Sclerosis; Alzheimer Disease; Mild Cognitive Impairment
Massachusetts General Hospital
 2022-12-05 PHASE1; PHASE2
NCT04901325 COMPLETED
Pyoderma Gangrenosum; Skin Diseases; Wound Heal; Pyoderma; Skin Ulcer
Oregon Health and Science University
 2023-10-03 PHASE2
NCT05852847 UNKNOWN
Immune Thrombocytopenia
Peking University People's Hospital
 2023-05-16 PHASE2
NCT06545110 UNKNOWN
Alopecia Areata
South Valley University
 2023-09-01 PHASE1
NCT05897372 TERMINATED
Diabetic Kidney Disease
Iain Bressendorff
 2023-08-01 PHASE2
NCT05074420 TERMINATED
Covid19; Corona Virus Infection
Eli Lilly and Company
 2021-12-21 PHASE3
NCT05016297 COMPLETED
Sjogren's Syndrome
Peking Union Medical College Hospital
 2022-07-14 PHASE2
NCT06475820 ACTIVE_NOT_RECRUITING
Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Malignant Lymphoma; Myelodysplastic Syndromes
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
 2023-12-01 PHASE2; PHASE3
NCT06114407 UNKNOWN
Spondyloarthritis, Axial
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
 2023-10-30 PHASE2
NCT05932524 UNKNOWN
Immune Thrombocytopenia
Peking University People's Hospital
 2023-07-07 PHASE2
NCT05781516 UNKNOWN
IgG4-related Disease With Eosinophilia
Wen Zhang
 2023-01-20
NCT05080218 COMPLETED
Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis
Jeffrey Curtis
 2021-11-15 PHASE4
NCT04321993 UNKNOWN
COVID-19
Lisa Barrett
 2020-04-17 PHASE2
NCT05827497 UNKNOWN
Rheumatoid Arthritis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
 2023-04-01 PHASE4
NCT03921554 COMPLETED
Aicardi Goutieres Syndrome
Adeline Vanderver, MD
 2019-06-03 PHASE2
NCT07645430 COMPLETED
Alopecia Areata
Benha University
 2023-01-01
NCT06662721 COMPLETED
Takayasu Arteritis
Liu Tian
 2023-04-03 PHASE2
NCT03755466 UNKNOWN
Rheumatoid Arthritis
Shinshu University
 2018-11-21 PHASE2
NCT03945760 COMPLETED
Allergic Contact Dermatitis
Wright State Physicians
 2020-09-14 EARLY_PHASE1
NCT05660655 COMPLETED
Rheumatoid Arthritis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
 2022-10-01 PHASE4
NCT04208464 COMPLETED
Idiopathic Inflammatory Myopathies
University of Manchester
 2021-10-07 PHASE2
NCT05263505 TERMINATED
Mucous Membrane Pemphigoid; Cicatrizing Conjunctivitis
Washington University School of Medicine
 2022-02-21 PHASE2
NCT04027101 COMPLETED
Polymyalgia Rheumatic (PMR)
University Hospital, Brest
 2020-12-01 PHASE2
NCT04088409 ACTIVE_NOT_RECRUITING
Uveitis
Eli Lilly and Company
 2019-10-16 PHASE3
NCT04890626 COMPLETED
SARS-CoV-2 Infection
Instituto de Investigación Hospital Universitario La Paz
 2020-04-04 PHASE3
NCT05446831 UNKNOWN
ITP; Immune Thrombocytopenia
Peking University People's Hospital
 2022-07-13 PHASE2
NCT05686746 UNKNOWN
Lupus or SLE; Nephritis
Assiut University
 2022-06-01 PHASE2; PHASE3
NCT05188521 COMPLETED
Cutaneous Lichen Planus
Aaron R. Mangold
 2022-01-11 PHASE2
NCT04822584 COMPLETED
Vitiligo
University Hospital, Bordeaux
 2021-07-16 PHASE2
NCT04517253 TERMINATED
Nakajo-Nishimura Syndrome; Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome; STING-Associated Vasculopathy With Onset in Infancy; Aicardi Goutieres Syndrome
Eli Lilly and Company
 2020-10-27 PHASE2; PHASE3
NCT05361109 WITHDRAWN
Dermatomyositis
University of Washington
 2022-06-01 PHASE2
NCT05238896 TERMINATED
Rheumatoid Arthritis
Assistance Publique - Hôpitaux de Paris
 2022-06-27 PHASE4
NCT04774224 COMPLETED
Type 1 Diabetes
St Vincent's Institute of Medical Research
 2020-10-30 PHASE2
NCT04891133 TERMINATED
COVID-19; Emerging Infectious Disease
Oslo University Hospital
 2021-06-03 PHASE2; PHASE3
NCT02759731 COMPLETED
Chronic Graft vs Host Disease; Chronic Graft-Versus-Host Disease
National Cancer Institute (NCI)
 2016-11-01 PHASE1; PHASE2
NCT05082714 COMPLETED
COVID-19
University Hospital of Patras
 2021-10-20
NCT03952559 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2019-05-24 PHASE3
NCT03843125 TERMINATED
Systemic Lupus Erythematosus
Eli Lilly and Company
 2019-09-09 PHASE3
NCT05056558 UNKNOWN
Covid19
Incepta Pharmaceuticals Ltd
 2021-10 PHASE3
NCT04832880 UNKNOWN
Covid19
ASST Fatebenefratelli Sacco
 2021-04-06 PHASE3
NCT03773978 COMPLETED
Juvenile Idiopathic Arthritis
Eli Lilly and Company
 2018-12-17 PHASE3
NCT04970719 WITHDRAWN
COVID-19 Pneumonia
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
 2021-07-10 PHASE3
NCT04131738 COMPLETED
Graft-versus-host-disease; Graft Vs Host Disease
Washington University School of Medicine
 2020-04-07 PHASE1
NCT05279391 UNKNOWN
COVID-19 Severe Respiratory Failure
Democritus University of Thrace
 2020-10-25
NCT03616912 TERMINATED
Systemic Lupus Erythematosus
Eli Lilly and Company
 2018-08-02 PHASE3
NCT03559270 TERMINATED
Atopic Dermatitis
Eli Lilly and Company
 2018-06-27 PHASE3
NCT03701789 UNKNOWN
Rheumatoid Arthritis; Bone Density; Finger Joints
University of Erlangen-Nürnberg Medical School
 2018-09-11 PHASE3
NCT03616964 COMPLETED
Systemic Lupus Erythematosus
Eli Lilly and Company
 2018-08-02 PHASE3
NCT04340232 WITHDRAWN
COVID-19
University of Colorado, Denver
 2021-03 PHASE2; PHASE3
NCT05006768 COMPLETED
Healthy
Genuine Research Center, Egypt
 2021-05-05 PHASE1
NCT04346147 UNKNOWN
COVID-19 Pneumonia
Hospital Universitario de Fuenlabrada
 2020-05-07 PHASE2
NCT04640168 COMPLETED
COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)
 2020-12-02 PHASE3
NCT04373044 TERMINATED
Symptomatic COVID-19 Infection Laboratory-Confirmed
University of Southern California
 2020-05-01 PHASE2
NCT04390464 UNKNOWN
COVID19
Cambridge University Hospitals NHS Foundation Trust
 2020-05-08 PHASE4
NCT03026504 COMPLETED
Arteritis, Giant Cell
Matthew J Koster
 2017-03-09 PHASE2
NCT04693026 UNKNOWN
Covid19; Covid-19 ARDS
M Abdur Rahim Medical College and Hospital
 2020-09-10 PHASE3
NCT04421027 COMPLETED
COVID-19
Eli Lilly and Company
 2020-06-12 PHASE3
NCT03570749 COMPLETED
Alopecia Areata
Eli Lilly and Company
 2018-09-24 PHASE2; PHASE3
NCT03899259 COMPLETED
Alopecia Areata
Eli Lilly and Company
 2019-07-08 PHASE3
NCT04916756 COMPLETED
Sjogren's Syndrome
Peking Union Medical College Hospital
 2020-01-16 PHASE1; PHASE2
NCT01885078 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2013-06-27 PHASE3
NCT03334435 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2018-03-28 PHASE3
NCT04399798 UNKNOWN
Corona Virus Infection
Fondazione IRCCS Policlinico San Matteo di Pavia
 2020-05-15 PHASE2
NCT04401579 COMPLETED
COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)
 2020-05-08 PHASE3
NCT04393051 UNKNOWN
Covid-19; SARS-CoV 2; SARS Pneumonia
Azienda Ospedaliero, Universitaria Pisana
 2020-05-20 PHASE2
NCT04320277 UNKNOWN
Pharmacological Action
Hospital of Prato
 2020-05-16 PHASE2; PHASE3
NCT04358614 COMPLETED
COVID; Pneumonia
Fabrizio Cantini
 2020-03-16 PHASE2; PHASE3
NCT03435081 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2018-02-20 PHASE3
NCT03428100 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2018-05-15 PHASE3
NCT03742973 TERMINATED
Primary Biliary Cholangitis
Eli Lilly and Company
 2019-03-28 PHASE2
NCT03733301 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2018-11-16 PHASE3
NCT03334422 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2017-11-27 PHASE3
NCT03334396 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2017-11-23 PHASE3
NCT02708095 COMPLETED
Systemic Lupus Erythematosus
Eli Lilly and Company
 2016-03-24 PHASE2
NCT03212638 COMPLETED
Healthy
Eli Lilly and Company
 2017-06-27 PHASE1
NCT02265705 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2014-10 PHASE3
NCT02576938 COMPLETED
Atopic Dermatitis
Eli Lilly and Company
 2016-02 PHASE2
NCT02758613 COMPLETED
Healthy
Eli Lilly and Company
 2016-05 PHASE1
NCT01710358 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2012-10 PHASE3
NCT02340104 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2015-01 PHASE1
NCT01711359 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2012-11 PHASE3
NCT02263911 COMPLETED
Healthy Participants
Eli Lilly and Company
 2014-11 PHASE1
NCT01683409 COMPLETED
Diabetic Kidney Disease
Eli Lilly and Company
 2012-08 PHASE2
NCT01721057 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2012-12 PHASE3
NCT01721044 COMPLETED
Rheumatoid Arthritis
Eli Lilly and Company
 2013-01 PHASE3
NCT01968057 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-10 PHASE1
NCT01960140 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-10 PHASE1
NCT01925144 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-10 PHASE1
NCT01924299 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-08 PHASE1
NCT01937026 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-09 PHASE1
NCT01896726 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-07 PHASE1
NCT01910311 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-08 PHASE1
NCT01859078 COMPLETED
Healthy Volunteers
Eli Lilly and Company
 2013-05 PHASE1
NCT01870388 COMPLETED
Liver Diseases; Hepatic Insufficiency
Eli Lilly and Company
 2013-06 PHASE1
NCT01490632 COMPLETED
Psoriasis; Skin Diseases; Skin Diseases, Papulosquamous
Eli Lilly and Company
 2011-12 PHASE2
NCT01469013 COMPLETED
Arthritis, Rheumatoid
Eli Lilly and Company
 2011-11 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-04)

Check the Baricitinib phosphate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Baricitinib phosphate selectively binds to and inhibits Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), preventing the phosphorylation of signal transducer and activator of transcription (STAT) proteins and suppressing downstream pro-inflammatory cytokine signaling cascades. By attenuating intracellular STAT activation and inflammatory mediator release, this compound reduces immune cell proliferation and viral cell entry pathways, directly providing therapeutic efficacy in clinical trial conditions such as rheumatoid arthritis, atopic dermatitis, and SARS-CoV-2 infection.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.